Edition:
United States

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

10.20USD
24 Feb 2017
Change (% chg)

$0.05 (+0.49%)
Prev Close
$10.15
Open
$10.10
Day's High
$10.25
Day's Low
$10.05
Volume
55,288
Avg. Vol
94,427
52-wk High
$13.40
52-wk Low
$6.01

CYTK.OQ

Chart for CYTK.OQ

About

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development... (more)

Overall

Beta: 1.79
Market Cap(Mil.): $413.27
Shares Outstanding(Mil.): 40.52
Dividend: --
Yield (%): --

Financials

  CYTK.OQ Industry Sector
P/E (TTM): 31.05 44.08 29.63
EPS (TTM): 0.33 -- --
ROI: 14.93 -3.35 12.96
ROE: 20.19 5.80 14.11

BRIEF-Cytokinetics Q4 EPS $0.16

* Cytokinetics, inc. Reports fourth quarter 2016 financial results

Feb 16 2017

BRIEF-Cytokinetics and Royalty Pharma announce $100 million transaction for Omecamtiv Mecarbil

* Cytokinetics and Royalty Pharma announce $100 million transaction for Omecamtiv Mecarbil

Feb 02 2017

BRIEF-Cytokinetics Q3 earnings per share $0.80

* Cytokinetics Inc reports third quarter 2016 financial results

Oct 27 2016

BRIEF-Cytokinetics announces first patient enrolled in VIGOR-ALS

* Cytokinetics announces first patient enrolled in VIGOR-ALS, an open-label extension clinical trial of tirasemtiv Source text for Eikon: Further company coverage:

Oct 18 2016

BRIEF-Cytokinetics announces early termination of Hart-Scott-Rodino waiting period

* Announces Early Termination Of Hart-Scott-Rodino waiting period for expanded collaboration with astellas

Sep 29 2016

BRIEF-Cytokinetics announces additional results from COSMIC-HF

* Announces additional results from COSMIC-HF to be presented at the HFSA Annual Scientific Meeting Source text for Eikon: Further company coverage:

Sep 09 2016

BRIEF-Cytokinetics reports initiation of IND-enabling studies

* Enabling studies for a next-generation fast skeletal muscle activator under co's collaboration with astellas

Sep 08 2016

BRIEF-Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3

* Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3 clinical development

Sep 01 2016

More From Around the Web

Earnings vs. Estimates